Imicilex

Imipenem/cilastatin, the active ingredient in Imicilex, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats a range of serious bacterial infections, including complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, skin and soft‑tissue infections, and septicemia, primarily in hospitalized adult patients requiring parenteral therapy.

GNH USA supplies Imicilex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to EU GMP standards and provides cold‑chain logistics for injectable products.

Imicilex (imipenem/cilastatin) is used for severe bacterial infections that require intravenous therapy. - Complicated intra‑abdominal infections: provides broad‑spectrum coverage to eradicate Gram‑negative, Gram‑positive and anaerobic pathogens. - Complicated urinary tract infections: eliminates resistant uropathogens in patients with upper urinary tract involvement. - Nosocomial pneumonia: treats hospital‑acquired lung infections caused by multidrug‑resistant organisms. - Skin and soft‑tissue infections: resolves deep tissue infections where oral agents are insufficient. - Septicemia: rapidly clears bloodstream infections caused by susceptible bacteria.

Adverse reactions to Imicilex may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient cranial discomfort. - Infusion site reactions: erythema, pain or phlebitis at the injection site. - Rash: mild maculopapular skin eruption.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: antibiotic‑associated severe diarrhea. - Elevated liver enzymes: hepatotoxicity in susceptible individuals. - Thrombocytopenia: marked reduction in platelet count.

Clinicians should observe several precautions when prescribing Imicilex to ensure patient safety. - Renal function: adjust dose in patients with impaired clearance to avoid accumulation. - Hypersensitivity: avoid in individuals with known allergy to carbapenems or β‑lactams. - Seizure risk: monitor neurologic status, particularly in patients with CNS disorders. - Valproic acid co‑administration: may reduce valproate levels and precipitate seizures. - Electrolyte imbalance: correct hypokalemia and hypomagnesemia before therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imicilex can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: reduces plasma valproate concentrations, increasing seizure risk. - Probenecid: may increase imipenem levels, heightening toxicity potential.

Moderate Interactions (Monitor Closely): - Warfarin: carbapenems may enhance anticoagulant effect; monitor INR. - Diuretics (e.g., furosemide): may exacerbate electrolyte disturbances; check electrolytes. - Rifampin: may induce hepatic enzymes and lower imipenem concentrations; adjust dose if needed.